These could result from technical differences in protein extraction protocols, a contribution of wild-type cells in the reimplanted model while in the primary lymphomas all cells have the RelA T505A mutation, differences in growth or cell cycle characteristics between primary and reimplanted lymphomas or the reduced number of lymphoma samples used in the RNA Seq and proteomics analysis versus the primary lymphoma analysis. The gene discussed is RELA; the disease is lymphoma.